Prior to Icon Bioscience, Dr. Tierney served as President & COO of Oceana Therapeutics, Inc., a specialty therapeutic company he co-founded in mid-2008. Oceana quickly established a global commercial network and by December 2011 was acquired by Salix Pharmaceuticals. In 2000, David was appointed President & CEO of Hydro Med Sciences (HMS), a research firm with a promising drug delivery platform. Under his leadership, HMS emerged as Valera Pharmaceuticals, a fully integrated, commercial, specialty pharma company that successfully completed an initial public offering in 2005. Valera has since been merged into Endo Pharmaceuticals. Prior to Valera, Dr. Tierney was President of Biovail Technologies, a drug delivery division of Biovail Corporation – a predecessor to Valeant Pharmaceuticals International. Earlier in his career, he served as Senior VP, Drug Development at Roberts Pharmaceutical and in a variety of management positions at Elan Corporation. Dr. Tierney received his medical degree from the Royal College of Surgeons in Dublin, Ireland.
David Tierney is the recipient of two Ernst & Young Entrepreneur of the Year® awards, first in 2005 and again in 2011. He was featured in the inaugural 2010 Irish Life Science 50 and in 2005, 2006, and 2011 was named one of the most inspiring people in the health sciences by PharmaVOICE 100.
Dr. Franklin is a Board Certified General Surgeon with over 20 years experience in clinical practice and over 15 years experience in the pharmaceutical space. He has served as Vice President & Chief Medical Officer at incubator sized firms to medium sized pharma companies including: Salix Pharmaceuticals, Oceana Pharmaceuticals, The Medicines Company, Esprit Pharmaceuticals and Odyssey Pharmaceuticals.
Dr. Franklin has acquired a deep bench of skills across all realms of medical affairs and clinical development.
Cathy joined Icon Bioscience, Inc. as the Vice President of Quality and Compliance in 2015. Her 30 years of experience includes laboratory operations, pharmaceutical and medical device manufacturing, and Phase I – IV clinical trial oversight. Prior to Icon, Cathy held senior level positions at Teva Pharmaceuticals, MAP Pharmaceuticals, Boston Scientific: Target and Pharmacia.